— Know what they know.
Not Investment Advice

PCVX NASDAQ

Vaxcyte, Inc.
1W: -11.5% 1M: -22.1% 3M: -19.0% YTD: +2.0% 1Y: +29.6% 3Y: -1.8% 5Y: +146.3%
$47.30
-0.09 (-0.19%)
 
Weekly Expected Move ±6.5%
$46 $49 $52 $56 $59
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 29 · $6.8B mcap · 132M float · 1.07% daily turnover · Short 58% of daily vol

Cash Flow Trends

Operating Cash Flow
-$656M -44.8% ▼
Capital Expenditures
$14M +38.9% ▲
5Y CAGR: +64.0%
Free Cash Flow
-$669M -40.9% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$214M -2184.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$100M-$223M-$402M-$464M-$767M
Depreciation & Amort.$3M$9M$10M$16M$25M
Stock-Based Comp.$11M$24M$49M$85M$139M
Change in Working Capital-$37M$13M$81M-$55M$20M
Other Non-Cash Items$2M$7M-$35M-$34M-$73M
Operating Cash Flow-$121M-$171M-$297M-$453M-$656M
— Investing Activities —
Capital Expenditures-$7M-$6M-$68M-$22M-$14M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$336M-$103M-$1.3B-$3.1B-$1.2B
Investment Sales$131M$183M$624M$1.2B$1.7B
Other Investing$26K$0$0-$97M-$43M
Investing Cash Flow-$212M$75M-$773M-$2.0B$437M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$4M$5M$4M$13M$2M
Financing Cash Flow$18M$862M$640M$2.4B$2M
Net Change in Cash-$316M$766M-$437M-$9M-$214M
Cash End of Period$70M$836M$399M$389M$175M
Free Cash Flow-$128M-$176M-$365M-$475M-$669M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms